ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
2024年10月16日 - 8:00PM
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma
company focused on accelerating the development and delivery of
transformative medicines in immunology, today announced the
formation of a scientific and patient advisory board comprised of
leading experts and advocates in thyroid eye disease (TED). This
group of advisors will provide important strategic input, clinical
expertise and patient perspectives as ACELYRIN prepares to advance
lonigutamab, a subcutaneously delivered IgG1 monoclonal antibody
targeting the anti-insulin-like growth factor 1 (IGF-1) receptor,
into Phase 3 clinical development for TED in the first quarter of
2025.
“Convening this esteemed group of clinical thought leaders and
patient advocates is an important step forward for us as we prepare
to advance lonigutamab into the pivotal Phase 3 program for TED,”
said Shephard (Shep) Mpofu, M.D., Chief Medical Officer of
ACELYRIN. “Each member brings distinct expertise spanning multiple
facets of TED including disease pathology, clinical trial
leadership and patient experience. We believe their collective
insights will position us extremely well to execute on our goal of
delivering the potentially best-in-class subcutaneous anti-IGF-1R
treatment for TED patients.”
Inaugural members of the ACELYRIN scientific and patient
advisory board are listed below; full bios are available on the
ACELYRIN website.
Scientific Advisors
- George J. Kahaly, MD, PhD, Professor of Medicine and
Endocrinology Metabolism and Chief Physician of the Endocrine
Outpatient Clinic at the Johannes Gutenberg University Medical
Center, Mainz, Germany;
- Andrea Lora Kossler, MD, FACS, Associate Professor of
Ophthalmology at Stanford University School of Medicine and
Director of the Oculofacial Plastic, Reconstructive Surgery and
Orbital Oncology Service at the Byers Eye Institute at
Stanford;
- Prem Subramanian, MD, PhD, Professor of Ophthalmology,
Neurology, and Neurosurgery, University of Colorado School of
Medicine; and
- Shoaib Ugradar, MD, Department of Orbital and Oculoplastic
Surgery, private practice, Beverly Hills, California.
Patient Advisor
- Christine Gustafson, Executive Director and CEO of the TED
Community Organization, the only global 501c3 nonprofit dedicated
to Thyroid Eye Disease.
About Thyroid Eye DiseaseThyroid Eye Disease
(TED) is a vision-threatening autoimmune disease in which there is
both inflammation and expansion of the tissues behind the eye,
resulting in eye bulging, known as proptosis, and the subsequent
inability to close the eyelids. Double vision, or diplopia, can
occur, as well as the potential for compression of the optic nerve,
which can lead to blindness. Thus, TED is a progressive, chronic
inflammatory disease. More than 100,000 people in the United States
are estimated to suffer from TED.
About LonigutamabLonigutamab is a humanized
IgG1 monoclonal antibody targeting the anti-insulin-like growth
factor 1 (IGF-1) receptor and is delivered subcutaneously. Relative
to standard of care, lonigutamab binds to a distinct epitope, which
results in internalization of the receptor within minutes, and in
preclinical binding and functional laboratory assays, it has been
shown to be 75-fold more potent. The characteristics of lonigutamab
that enable subcutaneous delivery also enable the potential for
longer-term, convenient dosing, which can potentially improve depth
and durability of clinical response.
About ACELYRINACELYRIN, INC. (Nasdaq: SLRN) is
focused on providing patients life-changing new treatment options
by identifying, acquiring, and accelerating the development and
commercialization of transformative medicines. ACELYRIN’s lead
program, lonigutamab, is a subcutaneously delivered monoclonal
antibody targeting IGF-1R being investigated for the treatment of
thyroid eye disease.
For more information about ACELYRIN, visit us at
www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking Statements This press release
contains forward-looking statements, including, but not limited to,
statements regarding ACELYRIN’s ability to address unmet needs of
patients, business plans and potential future benefits of our
pipeline. These forward-looking statements are based on ACELYRIN’s
current plans, objectives and projections, and are inherently
subject to risks and uncertainties that may cause ACELYRIN’s actual
results to materially differ from those anticipated in such
forward-looking statements. Such risks and uncertainties include,
without limitation, those associated with the successful completion
of development and regulatory activities with respect to ACELYRIN’s
product candidates, the risk that future results could differ
materially and adversely from early clinical data, and other risks
and uncertainties affecting ACELYRIN including those described from
time to time under the caption “Risk Factors” and elsewhere in
ACELYRIN’s current and future reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this
press release are made as of this date, and ACELYRIN undertakes no
duty to update such information except as required under applicable
law.
ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations
and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com
ACELYRIN (NASDAQ:SLRN)
過去 株価チャート
から 11 2024 まで 12 2024
ACELYRIN (NASDAQ:SLRN)
過去 株価チャート
から 12 2023 まで 12 2024